Test Price
2,800 AED✅ Home Collection Available
INF2 Gene Focal Segmental Glomerulosclerosis Type 5 (FSGS5) Genetic Test in UAE | 2,800 AED | DHA Licensed
Executive Summary & Core Metrics
Executive Summary
This advanced NGS-based genetic test detects pathogenic variants in the INF2 gene responsible for autosomal dominant focal segmental glomerulosclerosis type 5 (FSGS5), enabling precise diagnosis, familial cascade screening, and personalized nephrology management. Results are delivered with 99.9% diagnostic sensitivity under ISO 9001:2015 certified processing from our Dubai Healthcare City laboratory.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy and Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic post-test consultation with a Consultant Medical Genetics for result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The INF2 gene sequencing test for FSGS type 5 provides comprehensive analysis of all coding exons and flanking intronic regions using next-generation sequencing on the Illumina NovaSeq™ platform. This allows early detection of disease-causing variants—including single nucleotide variants, insertions/deletions, and copy number variants—before irreversible kidney damage occurs. A detailed clinical history form and genetic counselling session must be completed prior to sample collection.
| Metric | Our Test (NGS) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Diagnostic Precision | 99.9% | Up to 95% (targeted amplicon) |
| Methodology | NGS (Illumina NovaSeq™) with full exon coverage | Sanger sequencing of select hotspots |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks |
| Variant Detection | SNVs, indels, CNVs (bioinformatic pipeline) | Only point mutations |
Physician Insight & Safety Protocols
“This INF2 gene sequencing test should be interpreted in conjunction with clinical findings, renal biopsy histology, and family pedigree analysis. A negative result does not exclude other genetic or acquired causes of FSGS. I strongly recommend pre- and post-test genetic counselling to ensure informed decision-making and psychosocial support for affected families.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Medication Advisory
Do not discontinue any prescribed medication without prior consultation with your treating physician. This genetic test does not replace clinical monitoring or pharmacotherapy adjustments under specialist supervision.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion: Active systemic infection (e.g., sepsis), hemodynamic instability, or inability to provide informed consent per Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Minors require legal guardian accompaniment and co-consent in accordance with UAE family protection regulations.
- Emergency Red Flags — Sudden anuria, severe hypertension with pulmonary edema, rapidly rising serum creatinine above 500 µmol/L. Seek immediate emergency care.
Patient FAQ & Clinical Guidance
1. What is the INF2 FSGS5 genetic test and who needs it?
This test sequences the entire INF2 gene to identify mutations causing hereditary focal segmental glomerulosclerosis type 5. It is indicated for patients with steroid-resistant nephrotic syndrome, unexplained proteinuria, family history of kidney disease, or suspected familial FSGS. Results guide prognosis, treatment decisions, and family screening.
2. How is the sample collected and what preparation is needed?
A peripheral whole blood sample (EDTA tube), a dried blood spot on an FTA card, or extracted DNA is collected by our VIP mobile phlebotomist. A clinical history form and genetic counselling session must be completed beforehand. No fasting is required.
3. When will I receive results and how are they explained?
Results are delivered within 3 to 4 weeks via a secure online portal, accompanied by a telephonic consultation with a Consultant Medical Genetics who interprets the variants, discusses clinical implications, and outlines personalized follow-up plans.
UAE Regulatory & Data Privacy Adherence
Our laboratory operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access-controlled, and processed within UAE jurisdiction. The laboratory holds ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) and is licensed by the Dubai Health Authority (DHA Facility License No. 1143).
Clinical & Logistical Metadata
| Test Name | INF2 Gene Focal Segmental Glomerulosclerosis Type 5 (FSGS5) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA), Dried Blood Spot (FTA Card), or Extracted DNA |
| Methodology Used | Next-Generation Sequencing (NGS) — Illumina NovaSeq™ with Full Exon Coverage |
| ICD-10-CM Code | N04.1 |
| LOINC Code | 21636-6 |
| DHA Facility License & Laboratory Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians